Propanc Biopharma Investigates "Mesenchymal Drift" to Reverse Chronic Diseases Defined by Altos Labs

Stock Information for Propanc Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Propanc Biopharma Inc.

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results
Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
Propanc Biopharma Receives Certificate of Grant for "Proenzyme Composition" Patent from US Patent & Trademark Office

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.